P2Y12 antagonism: promises and challenges
Center for Platelet Function Studies
Acute Coronary Syndrome; Angioplasty, Transluminal, Percutaneous Coronary; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Education, Medical, Continuing; Female; Humans; Male; Maximum Tolerated Dose; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Risk Assessment; Survival Analysis; Ticlopidine; Treatment Outcome
Life Sciences | Medicine and Health Sciences
The P2Y12 antagonist clopidogrel has a well-established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary syndromes. However, several challenges remain, including the relatively slow onset of action of clopidogrel and the phenomenon of clopidogrel response variability or "resistance". Novel P2Y12 antagonists, including prasugrel, AZD6140, and cangrelor, have a faster onset of action, as well as more potent, and less variable, inhibition of platelet function ex vivo. Whether this promise will be translated into clinical benefit for patients will be determined by the results of ongoing phase 3 clinical trials.
Rights and Permissions
Citation: Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s33-8. Epub 2008 Jan 3. Link to article on publisher's site
DOI of Published Version
Arteriosclerosis, thrombosis, and vascular biology
Michelson, Alan D., "P2Y12 antagonism: promises and challenges" (2008). Open Access Articles. 1994.